Special Issue "Advances in Drug Design"

Guest Editor
Dr. Arthur Gomtsyan
Abbott Laboratories, 100 Abbott Park Road, Department R4PM, Bldg. AP10, Abbott Park, IL 60064, USA
E-Mail: arthur.r.gomtsyan@abbott.com
Phone: +1 847 935 4214
Fax: +1 847 937 9195
Interests: medicinal chemistry; synthetic organic chemistry; drug design in the area of pain research targeting ion channels and enzymes

Dear Colleagues,

Productivity of the pharmaceutical industry measured in terms of a number of approved drugs has been in decline over the last several decades. New creative approaches in drug design have been put in place to reverse that trend. Structure-based drug design that relies on high resolution 3D structures of drug targets is being complimented with fragment-based drug design approach which utilizes NMR spectroscopy to shorten the time of lead generation. On the other hand, closer attention is drawn to a drug-likeness of molecules – molecular weight, solubility, lipophilicity, etc. Lipinski's rule of five or its modifications are gaining prominence in medicinal chemistry decision making. Cheminformatic tools are becoming part of arsenal for medicinal chemists. Drug design takes into account not only pharmacological properties, but also potential toxicological effects of the molecules. Potential for reactive metabolite formation and protein covalent binding now can be assessed with various successes in vitro to predict idiosyncratic toxicity in clinic. New procedures including in silico models can be implemented to predict pharmacokinetic properties of the compounds.
Prevailing dogma in drug discovery that values selective compounds the most is getting challenged with a concept of polypharmacology, which suggests that multitargeted drugs, compared with selective drugs, may display better efficacy in clinic. As far as the mechanism of drug action goes, concept of allosteric modulation is more widely employed in a number of therapeutic areas.

Dr. Arthur Gomtsyan
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• structure-based drug design
• fragment-based drug design
• drug-likeness, rule of five
• cheminformatics
• predictive methodologies for ADME and drug toxicity
• polypharmacology
• allosteric modulators